Pirarreumol "B" en es it fr

Pirarreumol "B" Brand names, Pirarreumol "B" Analogs

Pirarreumol "B" Brand Names Mixture

  • Alka Phenyl Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)
  • Alka Phenylbutazone Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)
  • Phenylone Plus Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)

Pirarreumol "B" Chemical_Formula


Pirarreumol "B" RX_link

No information avaliable

Pirarreumol "B" fda sheet

Pirarreumol "B" msds (material safety sheet)

Pirarreumol_"B" MSDS

Pirarreumol "B" Synthesis Reference

Ullmann's Encyklopaedie der Technischen Chemie 13, 298 (1962)

Pirarreumol "B" Molecular Weight

308.374 g/mol

Pirarreumol "B" Melting Point

105 oC

Pirarreumol "B" H2O Solubility

47.5 mg/L

Pirarreumol "B" State


Pirarreumol "B" LogP


Pirarreumol "B" Dosage Forms

Bolus; Liquid; Paste; Powder; Solution; Tablet

Pirarreumol "B" Indication

For the treatment of backache and ankylosing spondylitis

Pirarreumol "B" Pharmacology

Phenylbutazone is a synthetic, pyrazolone derivative. It is a nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties and arise from its ability to reduce production of prostaglandin H and prostacyclin. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostacylcin causes vascular constriction platelet disaggregation

Pirarreumol "B" Absorption

No information avaliable

Pirarreumol "B" side effects and Toxicity

Oral, LD50 = 238 mg/kg (mouse); Oral, LD50 = 781 mg/kg (rabbit); Oral, LD50 = 245 mg/kg (rat); Oral, LD50 = 375 mg/kg (rat)

Pirarreumol "B" Patient Information

No information avaliable

Pirarreumol "B" Organisms Affected

Humans and other mammals